ESMO Media Releases

The course aims to attract medical students to the medical oncology profession to ensure there are sufficient numbers to care for the rising numbers of cancer patients

Patients with metastatic colorectal cancer (mCRC) that are mutation-free in the KRAS, NRAS, BRAF and PIK3CA genes showed significant benefit from continuing anti-epidermal growth factor receptor (EGFR) therapy beyond progression following first-line chemotherapy and an anti-EGFR monoclonal antibody

Researchers announced that the phase IIIb CONSIGN study has confirmed the benefit, with safety profile and progression free survival similar to phase III trial results

The multicentre, open label, randomised phase III trial evaluated the NK1 antagonist aprepitant for the prevention of nausea and vomiting induced by oxaliplatin-based chemotherapy in Japanese patients with colorectal cancer

A total of 6,128 patients were included in the analysis, which showed that patients with the lowest BMI had a significantly shorter overall survival than patients in the other BMI categories

The ESMO President for the 2018-2019 period will be Josep Tabernero

The scale offers a rational, structured and consistent approach to ‘stratify’ a drug’s clinically meaningful benefit

To mark the European Week against Cancer, ESMO is highlighting positive developments and challenges to come from the EU's Clinical Trials Regulation

Circulating tumour DNA in blood a valid option for EGFR testing in patients who do not have accessible tumour tissue, study shows

Lack of test results may impact treatment effectiveness and survival, survey in Europe, Asia and US reveals

Survey shows that many live in ‘denial’ of the real risks of smoking even a small number of cigarettes a day

Many patients with BRAF-mutant cancers benefit from treatment with BRAF inhibitors, European researchers report at ELCC